Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oculis Holding AG - Ordinary shares
(NQ:
OCS
)
22.70
+22.70 (+782831.03%)
Streaming Delayed Price
Updated: 2:43 PM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oculis Holding AG - Ordinary shares
< Previous
1
2
Next >
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 29, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
May 14, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q1 2026 Financial Results and Provides Company Update
May 11, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
May 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 05, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming Investor Conferences
April 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
March 16, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming Investor Conferences
March 05, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
March 03, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Appoints Katie Kazem as Chief Legal Officer
February 17, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
January 08, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
January 06, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q3 2025 Financial Results and Provides Company Update
November 10, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming November Investor Conferences
November 05, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
October 30, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
October 14, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
October 06, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
September 22, 2025
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
From
Oculis Holding AG
Via
GlobeNewswire
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
September 04, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
September 01, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming September Investor Conferences
August 28, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
August 25, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q2 2025 Financial Results and Provides Company Update
August 21, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 12, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Upsized Loan Facility to Access up to CHF 100 million
August 01, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Results of 2025 Annual General Meeting
June 05, 2025
From
Oculis Holding AG
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
